Home/Specialty/Neurology/Computerized Behavioral Therapy Device For Substance Use Disorders/Somryst™

PEAR THERAPEUTICS, INC. 1 Somryst™

Company Name

PEAR THERAPEUTICS, INC.

Catalog Number

1

Description

Somryst is a prescription-only digital therapeutic intended to provide a neurobehavioral intervention (Cognitive Behavioral Therapy for Insomnia - CBT-I) in patients 22 years of age and older with chronic insomnia. Somryst treats chronic insomnia by improving a patient's insomnia symptoms.Somryst uses sleep restriction and consolidation, limiting the time a patient spends in bed to match the amount of time they sleep. This treatment technique can increase risks to some patients whose pathophysiology may be worsened. Because of this, it is not appropriate for everyone.

Have questions or need more information? Contact Us

Pricing
Summary

Price Not Available

Out of Stock

Interested in this product?
Contact us or login to add to your watchlist.

Related Items

PEAR THERAPEUTICS, INC. 1 reSET-O® Non-Monetary CM

reSET-O is intended to increase retention of patients with Opioid Use Disorder (OUD) in outpatient treatment by providing cognitive behavioral therapy, as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for patients 18 years or older who are currently under the supervision of a clinician. reSET-O is indicated as a prescription-only digital therapeutic. This configuration of reSET-O is intended to provide virtual incentives to patients based on the Contingency management system.

PEAR THERAPEUTICS, INC. 1 reSET-O®

reSET-O is intended to increase retention of patients with Opioid Use Disorder (OUD) in outpatient treatment by providing cognitive behavioral therapy, as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for patients 18 years or older who are currently under the supervision of a clinician. reSET-O is indicated as a prescription-only digital therapeutic. This configuration of reSET-O is intended to provide virtual incentives as well as monetary incentives to the patients based on the Contingency management system.

PEAR THERAPEUTICS, INC. 1 reSET-O®

reSET-O® is intended to increase retention of patients with opioid use disorder (OUD) in outpatient treatment by providing cognitive behavioral therapy, as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for patients 18 years or older who are currently under the supervision of a clinician. reSET-O is indicated as a prescription-only digital therapeutic.

Allen A-30522-2-A8 Finger Trap

Finger Trap Large

ARTHREX, INC. AR-9300OBT Arthrex®

Burr, Oval, 10 flute, 3.0mm

General & Plastic Surgery

petrafocon A hem-larafilcon A

SYNERGEYES, INC. petrafocon A hem-larafilcon A SynergEyes casted button

SynergEyes petrafocon A hem-larafilcon A casted button

paflufocon D – hem-iberfilcon A

SYNERGEYES, INC. paflufocon D – hem-iberfilcon A Synergeyes Casted Buttons

Synergeyes paflufocon D – hem-iberfilcon A Casted Buttons

PEAR THERAPEUTICS, INC. 1 reSET-O® Non-Monetary CM

reSET-O is intended to increase retention of patients with Opioid Use Disorder (OUD) in outpatient treatment by providing cognitive behavioral therapy, as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for patients 18 years or older who are currently under the supervision of a clinician. reSET-O is indicated as a prescription-only digital therapeutic. This configuration of reSET-O is intended to provide virtual incentives to patients based on the Contingency management system.

PEAR THERAPEUTICS, INC. 1 reSET-O®

reSET-O is intended to increase retention of patients with Opioid Use Disorder (OUD) in outpatient treatment by providing cognitive behavioral therapy, as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for patients 18 years or older who are currently under the supervision of a clinician. reSET-O is indicated as a prescription-only digital therapeutic. This configuration of reSET-O is intended to provide virtual incentives as well as monetary incentives to the patients based on the Contingency management system.

PEAR THERAPEUTICS, INC. 1 reSET-O®

reSET-O® is intended to increase retention of patients with opioid use disorder (OUD) in outpatient treatment by providing cognitive behavioral therapy, as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for patients 18 years or older who are currently under the supervision of a clinician. reSET-O is indicated as a prescription-only digital therapeutic.

PEAR THERAPEUTICS, INC. 1 reSET-O® Non-Monetary CM

reSET-O is intended to increase retention of patients with Opioid Use Disorder (OUD) in outpatient treatment by providing cognitive behavioral therapy, as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for patients 18 years or older who are currently under the supervision of a clinician. reSET-O is indicated as a prescription-only digital therapeutic. This configuration of reSET-O is intended to provide virtual incentives to patients based on the Contingency management system.

PEAR THERAPEUTICS, INC. 1 reSET-O®

reSET-O is intended to increase retention of patients with Opioid Use Disorder (OUD) in outpatient treatment by providing cognitive behavioral therapy, as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for patients 18 years or older who are currently under the supervision of a clinician. reSET-O is indicated as a prescription-only digital therapeutic. This configuration of reSET-O is intended to provide virtual incentives as well as monetary incentives to the patients based on the Contingency management system.

PEAR THERAPEUTICS, INC. 1 reSET-O®

reSET-O® is intended to increase retention of patients with opioid use disorder (OUD) in outpatient treatment by providing cognitive behavioral therapy, as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for patients 18 years or older who are currently under the supervision of a clinician. reSET-O is indicated as a prescription-only digital therapeutic.

Additional Details

Device Identifier

10851580008255

Is RX

Yes

Is Over the Counter

No

Requires Sterilization

No

Is Sterile

No

Is Single Use

No

Categories

Barcode Mapping

Unit of Measurement	Eaches	GTIN
Each	1	10851580008255
Each	1	96439-0030-01